Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 6, 2011, Pages 515-527

  Chang, Yu Hung ^a   Chang, Dao Ming ^a   Lin, Kun Cheng ^a   Shin, Shyi Jang ^b   Lee, Yau Jiunn ^a  

^a Lee's Endocrinologic Clinic   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular diseases; Insulin resistance; Metabolic syndrome; Obesity; T2DM; Visfatin

Indexed keywords

INSULIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

CARDIOVASCULAR DISEASE; DRUG SENSITIVITY; HUMAN; INSULIN RESISTANCE; MEDLINE; META ANALYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTION; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; REVIEW; SYSTEMATIC REVIEW;

ADULT; AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; OVERWEIGHT;

EID: 80052583612     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1201     Document Type: Review

References (69)

1. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307(5708): 426-430.
2. Fukuhara A, Matsuda M, Nishizawa M, et al. Retraction. Science 2007; 318(5850): 565.
3. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91(1): 295-299.
4. Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114(10): 544-548.
5. Dogru T, Sonmez A, Tasci I, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76(1): 24-29.
6. Fernandez-Real JM, Moreno JM, Chico B, Lopez-Bermejo A, Ricart W. Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care 2007; 30(3): 616-621.
7. Alghasham AA, Barakat YA. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy. Saudi Med J 2008; 29(2): 185-192.
8. Yilmaz MI, Saglam M, Qureshi AR, et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008; 23(5): 1621-1627.
9. Zhu J, Schott M, Liu R, et al. Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm Metab Res 2008; 40(11): 801-805.
10. Esteghamati A, Alamdari A, Zandieh A, et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract 2010; 91(2): 154-158.
11. Eyileten T, Sonmez A, Saglam M, et al. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton) 2010; 15(2): 225-229.
12. Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2010; 118(2): 75-80.
13. Kang YS, Song HK, Lee MH, Ko GJ, Cha DR. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes Res Clin Pract 2010; 89(2): 141-149.
14. El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011; 60(1): 63-70.
15. Hammarstedt A, Pihlajamaki J, Rotter Sopasakis V, et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006; 91(3): 1181-1184.
16. Jian WX, Luo TH, Gu YY, et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 2006; 23(9): 967-973.
17. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55(10): 2871-2875.
18. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56(4): 565-570.
19. Tsiotra PC, Tsigos C, Yfanti E, et al. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 2007; 39(10): 758-763.
20. Retnakaran R, Youn BS, Liu Y, et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 2008; 69(6): 885-893.
21. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56(4): 451-458.
22. Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol 2007; 157(4): 437-442.
23. Malavazos AE, Ermetici F, Cereda E, et al. Epicardial fat thickness. relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis 2008; 18(8): 523-530.
24. Panidis D, Farmakiotis D, Rousso D, et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med 2008; 19(6): 406-412.
25. Sheu WH, Chang TM, Lee WJ, et al. Effect of weight loss on proinflammatory state of mononuclear cells in obese women. Obesity (Silver Spring) 2008; 16(5): 1033-1038.
26. Hallschmid M, Randeva H, Tan BK, Kern W, Lehnert H. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes 2009; 58(3): 637-640.
27. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56(8): 1131-1134.
28. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007; 30(4): 323-326.
29. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69(6): 878-884.
30. Iacobellis G, Iorio M, Napoli N, et al. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest 2010; 34(1): e12-e15.
31. Schutte AE, Huisman HW, Schutte R, et al. Adipokines and cardiometabolic function. How are they interlinked? Regul Pept 2010; 164(2-3): 133-138.
32. Unluturk U, Harmanci A, Yildiz BO, Bayraktar M. Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol (Oxf) 2010; 72(4): 469-474.
33. Kim JH, Kim SH, Im JA, Lee DC. The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas 2010; 67(1): 67-71.
34. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009; 71(2): 202-207.
35. Lu LF, Yang SS, Wang CP, et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis 2009; 18(5): 354-359.
36. Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91(8): 3165-3170.
37. Shea J, Randell E, Vasdev S, Wang PP, Roebothan B, Sun G. Serum retinol-binding protein 4 concentrations in response to short-term overfeeding in normal-weight, overweight, and obese men. Am J Clin Nutr 2007; 86(5): 1310-1315.
38. Lin CC, Lai MM, Li TC, et al. Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract 2009; 85(1): 24-29.
39. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP, Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring) 2006; 14(11): 1886-1889.
40. Fasshauer M, Bluher M, Stumvoll M, Tonessen P, Faber R, Stepan H. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol (Oxf) 2007; 66(3): 434-439.
41. Sun G, Bishop J, Khalili S, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007; 85(2): 399-404.
42. Wang P, van Greevenbroek MM, Bouwman FG, et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007; 454(6): 971-976.
43. Seo JA, Jang ES, Kim BG, et al. Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res Clin Pract 2008; 79(1): 108-111.
44. Choi KM, Lee JS, Kim EJ, et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008; 158(2): 203-207.
45. Erdem G, Naharci MI, Demirtas A, et al. Therapeutic lifestyle change intervention in metabolic syndrome decreases plasma visfatin levels. Anatolian J Clin Investig 2008; 2(2): 58-62.
46. Kovacikova M, Vitkova M, Klimcakova E, et al. Visfatin expression in subcutaneous adipose tissue of pre-menopausal women. relation to hormones and weight reduction. Eur J Clin Invest 2008; 38(7): 516-522.
47. Mitterberger MC, Mattesich M, Klaver E, et al. Adipokine profile and insulin sensitivity in formerly obese women subjected to bariatric surgery or diet-induced long-term caloric restriction. J Gerontol A Biol Sci Med Sci 2010; 65(9): 915-923.
48. Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007; 56(9): 1216-1220.
49. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.
50. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2005;.
51. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in Epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283(15): 2008-2012.
52. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5(1): 13.
53. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-1558.
54. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-560.
55. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-634.
56. Costford SR, Bajpeyi S, Pasarica M, et al. Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab 2010; 198(1): E117-E126.
57. Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49(4): 744-747.
58. Garten A, Petzold S, Barnikol-Oettler A, et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 2010; 391(1): 376-381.
59. Kang YS, Song HK, Lee MH, et al. Visfatin is upregulated in type-2 diabetic rats and targets renal cells. Kidney Int 2010; 78(2): 170-181.
60. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49(8): 1909-1914.
61. Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6(5): 363-375.
62. Brown JE, Onyango DJ, Ramanjaneya M, et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 2010; 44: 171-178.
63. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 2008; 12(4): 1395-1403.
64. Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783(5): 886-895.
65. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115(8): 972-980.
66. Adya R, Tan BK, Chen J, Randeva HS. Nuclear factor-kappa B induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 roduction and activation. Diabetes Care 2008; 31(4): 758-760.
67. Romacho T, Azcutia V, Vazquez-Bella M, et al. Extracellular PBEF /NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009; 52(11): 2455-2463.
68. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92(12): 4783-4791.
69. Nusken KD, Nusken E, Petrasch M, Rauh M, Dotsch J. Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 2007; 382(1-2): 154-156.